Management of malignant pleural mesothelioma: A French multicenter retrospective study (GFPC 0802 study)
BMC Cancer, ISSN: 1471-2407, Vol: 15, Issue: 1, Page: 857
2015
- 34Citations
- 29Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations34
- Citation Indexes32
- 14
- CrossRef7
- Clinical Citations1
- PubMed Guidelines1
- Policy Citations1
- Policy Citation1
- Captures29
- Readers29
- 29
Article Description
Background: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients' profiles and management in daily practice in France. Methods: Observational retrospective study. Data were collected from medical files. All patients with histologically proven MPM diagnosed from January 2005 to December 2008 were included in the participating sites. Results: Four hundred and six patients were included in 37 sites: mean age 68.9±9.8years, male predominance (sex ratio 3.27), latency of the disease 45.7years, epithelioïd type 83%. Diagnosis was made using thoracoscopy in 80.8% of patients. Radical surgery was performed in 6.2% of cases. Chemotherapy was administered to 74.6% of patients. First line regimens consisted mainly of platinum+pemetrexed (91%) or pemetrexed alone (7%). Objective response rate was 17.2% and another 41.6% of patients experienced disease stabilization. Half of these patients underwent second line chemotherapy (platinium+pemetrexed 31.6%, pemetrexed alone 24.6%), resulting in a 6% response rate. Third-line chemotherapy (56 patients) yielded disease control in 5.4% of cases. Conclusions: The management of MPM in France is usually in accordance with guidelines. Response rates are somewhat lower than those described in clinical trials.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84946398580&origin=inward; http://dx.doi.org/10.1186/s12885-015-1881-x; http://www.ncbi.nlm.nih.gov/pubmed/26546402; http://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1881-x; https://dx.doi.org/10.1186/s12885-015-1881-x; https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1881-x
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know